{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-001591","form_type":"8-K","ticker":"XAGE","cik":"0001842939","company_name":"Longevity Health Holdings, Inc.","filed_at":"2023-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.067933+00:00","generated_at":"2026-06-20T20:27:55.399412+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Alpha Healthcare Acquisition Corp. III merges with Carmell Therapeutics at $150M implied equity value","bullets":["Carmell shareholders receive 15M ALPA Class A shares; implied Carmell equity value $150M.","Combined company expected market cap ~$328M; Carmell shareholders own ~46% post-close.","Transaction expected to close H1 2023; combined co. to list on Nasdaq as 'CTCX'.","Carmell is a Phase 2 biotech with allogeneic plasma-based biomaterials; FDA Fast Track for tibia fracture.","Rajiv Shukla to become Chairman, Randy Hubbell to serve as CEO of combined company."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-001591","json":"https://secwatch.observer/filing/0001193125-23-001591.json","markdown":"https://secwatch.observer/filing/0001193125-23-001591.md","text":"https://secwatch.observer/filing/0001193125-23-001591.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842939/000119312523001591/0001193125-23-001591-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842939/000119312523001591/d411625d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T20:27:55.399412+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"147f27fbfac0da5a3cb5de421af3a9561ee2c18d","claim":"Longevity Health Holdings, Inc. entered into Business Combination Agreement with Carmell Therapeutics Corporation valued at an implied Carmell equity value of $150,000,000 (effective 2023-01-04).","evidence_excerpt":"On January 4, 2023, Alpha Healthcare Acquisition Corp. III, a Delaware corporation (the \" Company \"), entered into a business combination agreement (the \" Business Combination Agreement \") by and among the Company, Candy Merger Sub, Inc., a Delaware corporation (\" Merger Sub \"), and Carmell Therapeutics Corporation, a Delaware corporation (\" Carmell \").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1842939/000119312523001591/0001193125-23-001591-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Carmell Therapeutics Corporation"},{"label":"Value","value":"an implied Carmell equity value of $150,000,000"},{"label":"Effective","value":"2023-01-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}